Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Bigazzi

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|March 21, 2007
Increased cardiovascular events in hypertensive patients with insulin resistance: a 13-year follow-upRoberto Bigazzi, Stefano Bianchi, Enrica Buoncristiani, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 4, 2003
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney diseaseStefano Bianchi, Roberto Bigazzi, Alberto Caiazza, et al.
Journal of Nephrology|September 3, 2011
Do HMG-CoA reductase inhibitors improve kidney function? The saga continuesVito M Campese, Elaine Ku, Roberto Bigazzi, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|January 9, 2010
Angiotensin receptor blocker telmisartan improves insulin sensitivity in peritoneal dialysis patientsAntonio Cioni, Caterina Sordini, Ivo Cavallini, et al.
American Journal of Hypertension|April 4, 2006
Metabolic risk factors and markers of cardiovascular and renal damage in overweight subjectsRoberto Bigazzi, Stefano Bianchi, Valentina Batini, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 10, 2011
Soluble CD40 ligand is predictive of combined cardiovascular morbidity and mortality in patients on haemodialysis at a relatively short-term follow-upGiovambattista Desideri, Vincenzo Panichi, Sabrina Paoletti, et al.
Journal of Nephrology|December 29, 2010
Management of secondary hyperparathyroidism in Italy: results of the Italian FARO surveySandro Mazzaferro, Diego Brancaccio, Piergiorgio Messa, et al.
Journal of Nephrology|February 18, 2020
Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of NephrologyRoberto Pontremoli, Vincenzo Bellizzi, Stefano Bianchi, et al.
Blood Purification|March 14, 2015
A pharmacoeconomic analysis of phosphate binders cost-effectiveness in the RISCAVID studyVincenzo Panichi, Alberto Rosati, Adriana Di Giorgio, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 29, 2008
Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID studyVincenzo Panichi, Giovanni M Rizza, Sabrina Paoletti, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|March 21, 2007
Increased cardiovascular events in hypertensive patients with insulin resistance: a 13-year follow-upRoberto Bigazzi, Stefano Bianchi, Enrica Buoncristiani, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 4, 2003
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney diseaseStefano Bianchi, Roberto Bigazzi, Alberto Caiazza, et al.
Journal of Nephrology|September 3, 2011
Do HMG-CoA reductase inhibitors improve kidney function? The saga continuesVito M Campese, Elaine Ku, Roberto Bigazzi, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|January 9, 2010
Angiotensin receptor blocker telmisartan improves insulin sensitivity in peritoneal dialysis patientsAntonio Cioni, Caterina Sordini, Ivo Cavallini, et al.
American Journal of Hypertension|April 4, 2006
Metabolic risk factors and markers of cardiovascular and renal damage in overweight subjectsRoberto Bigazzi, Stefano Bianchi, Valentina Batini, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 10, 2011
Soluble CD40 ligand is predictive of combined cardiovascular morbidity and mortality in patients on haemodialysis at a relatively short-term follow-upGiovambattista Desideri, Vincenzo Panichi, Sabrina Paoletti, et al.
Journal of Nephrology|December 29, 2010
Management of secondary hyperparathyroidism in Italy: results of the Italian FARO surveySandro Mazzaferro, Diego Brancaccio, Piergiorgio Messa, et al.
Journal of Nephrology|February 18, 2020
Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of NephrologyRoberto Pontremoli, Vincenzo Bellizzi, Stefano Bianchi, et al.
Blood Purification|March 14, 2015
A pharmacoeconomic analysis of phosphate binders cost-effectiveness in the RISCAVID studyVincenzo Panichi, Alberto Rosati, Adriana Di Giorgio, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 29, 2008
Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID studyVincenzo Panichi, Giovanni M Rizza, Sabrina Paoletti, et al.
Pageof 3